| Name | Title | Contact Details |
|---|
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
PBM consulting, provider nnetwork strategies, rebate benchmarking, global drug sourcing, client pricing, market assessments, MAC management, rebate aggregation.
Isto Biologics is an orthobiologics company dedicated to helping patients heal faster through advanced solutions for spine, orthopedics, sports and regenerative medicine.
BioVest International is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Stonewood Village Pharmacy is a Fort Smith, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.